304 related articles for article (PubMed ID: 25784654)
1. Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.
Vogel RI; Coughlin K; Scotti A; Iizuka Y; Anchoori R; Roden RB; Marastoni M; Bazzaro M
Oncotarget; 2015 Feb; 6(6):4159-70. PubMed ID: 25784654
[TBL] [Abstract][Full Text] [Related]
2. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
[TBL] [Abstract][Full Text] [Related]
3. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
7. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
Thomas S; Sharma N; Golden EB; Cho H; Agarwal P; Gaffney KJ; Petasis NA; Chen TC; Hofman FM; Louie SG; Schönthal AH
Cancer Lett; 2012 Dec; 325(1):63-71. PubMed ID: 22664238
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein deubiquitination by PR-619 activates the autophagic pathway in OLN-t40 oligodendroglial cells.
Seiberlich V; Borchert J; Zhukareva V; Richter-Landsberg C
Cell Biochem Biophys; 2013 Sep; 67(1):149-60. PubMed ID: 23686611
[TBL] [Abstract][Full Text] [Related]
9. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
[TBL] [Abstract][Full Text] [Related]
10. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Kou X; Yang Y; Jiang X; Liu H; Sun F; Wang X; Liu L; Liu H; Lin Z; Jiang L
Eur J Pharmacol; 2017 Oct; 813():161-171. PubMed ID: 28826913
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinase inhibition as a cancer therapeutic strategy.
D'Arcy P; Wang X; Linder S
Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
15. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
16. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
19. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]